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Abstract: Renal impairment (RI) is a relatively common complication of multiple myeloma,
which increases in frequency as disease becomes more advanced and recovery of renal
function becomes less likely as patients progress through lines of therapy. Clinical trials in the
relapsed/refractory multiple myeloma (RRMM) setting have not uniformly included patients
with RI or robustly reported their outcomes. Here, we review existing data among patients
with RI and RRMM across drug classes (including immunomodulatory agents, proteasome
inhibitors, monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor
T-cell therapies, and exportin-1 inhibitor) to provide an improved understanding of available
treatment options for this important population. We highlight data from pivotal clinical trials,
including data relating to renal response (as defined by the International Myeloma Working
Group) and discuss real-world experiences in patients with RI, where applicable. Despite
substantial advances in RRMM treatment, the presence of RI remains associated with reduced
overall survival. Consistent inclusion of patients with RI, and uniform reporting of their
outcomes, should be encouraged in future prospective trials of treatments for RRMM.
Keywords: multiple myeloma, refractory, relapsed, renal impairment, renal response
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Introduction
Renal impairment (RI) is present in up to 50% of
patients with multiple myeloma (MM) at diagnosis,1–3 and 2%–4% of patients with MM who present with RI require dialysis.4 As patients progress
through lines of therapy for MM, existing RI
often worsens.5 Of patients without RI at diagnosis, roughly 25% will develop RI during later
stages of disease.4 Recovery of renal function is
less likely in patients with relapsed/refractory MM
(RRMM) compared to those with newly diagnosed MM (NDMM).4
Renal damage in MM is primarily caused by the
toxic effects of monoclonal free light chains (FLCs),
which lead to a host of renal pathologies including
monoclonal cast nephropathy (MCN).1,3,4,6 The
International Myeloma Working Group (IMWG)

defines RI in MM as serum creatinine greater than
2 mg/dL or reduced creatinine clearance
(CrCl < 40 mL/min), either (or both) of which is
found to be the result of myeloma.1 For evaluation
of CrCl, estimated glomerular filtration rate
(eGFR) can be assessed via either the Modification
of Diet in Renal Disease (MDRD)7 or the Chronic
Kidney Disease Epidemiology Collaboration
(CKD-EPI)8,9 equation.
Studies have shown that RI is associated with
reduced overall survival (OS) and increased risk
of early mortality in MM,5,10,11 with some suggesting a correlation between outcomes and
degree of estimated glomerular filtration rate
(eGFR) decline.4,10 A recent meta-analysis12 of
six randomized controlled trials conducted
through 2019 found that RI conferred a higher
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Table 1. IMWG criteria for the definition of renal response to antimyeloma therapy.1.
Baseline eGFRa, mL/min/1.73 m2

Best CrCl responseb

Complete response

<50

⩾ 60 mL/min

Partial response

<15

30−59 mL/min

Minor response

<15

15−29 mL/min

15−29

30−59 mL/min

CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; IMWG, International Myeloma Working Group.
aeGFR is based on the Modification of Diet in Renal Disease formula or the Chronic Kidney Disease Epidemiology
Collaboration equation.
bRenal overall response defined as a best response of minor response or better.

relative risk of disease progression or death among
participants. Improvements in both OS and renal
function have been reported with novel treatments for RRMM, particularly when compared
to conventional chemotherapy.10 Though improve
ment in renal function is associated with improved
survival, OS remains inferior among patients with
baseline RI compared to those with no RI at MM
diagnosis.10,11
Several issues confound the evaluation of outcomes in patients with RI and MM: (1) lack of a
standardized definition of RI and renal recovery
across clinical trials, (2) exclusion of patients with
RI from trials or lack of clear reporting of enrollment criteria pertaining to renal dysfunction, (3)
the inherent shortfall of measuring renal function
in patients with acute kidney injury (AKI) using
equations developed for renal function estimation
in chronic kidney disease (CKD), and (4) establishing the correct cause of RI since the age group
of patients with MM commonly present with vascular and metabolic disorders.3,12
The aim of this review is to provide available efficacy and safety data for RRMM treatments
among patients with RI, with a focus on pivotal
clinical trials and real-world experience. Recent
advances seen with approved novel therapies
such as immunomodulatory drugs, proteasome
inhibitors (PIs), monoclonal antibodies, small
molecule inhibitors and antibody-drug conjugates (ADCs) will be highlighted, as well as
emerging data with cellular therapies. Special
attention will be given to analyses that detail
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renal response to therapy, particularly as defined
by the IMWG1 (Table 1).
Mechanisms of renal damage in MM
When present in normal amounts, monoclonal
FLCs are freely filtered at the glomerulus, endocytosed by proximal tubule cells, and catabolized. In
plasma cell dyscrasias such as MM, monoclonal
FLCs can reach concentrations that exceed the
absorptive and catabolic capacities of the proximal
tubule cells.4,6 Monoclonal FLCs that remain in
the proximal tubules can activate apoptotic pathways and cause intense inflammation that leads
to fibrosis, whereas those that reach the distal
nephron can interact with Tamm-Horsfall protein
(urothelin) to form aggregates that precipitate and
lead to cast formation and nephronal occlusion
(Figure 1).4 Roughly 90% of patients with MM
who present with AKI have the hallmark pathologic feature of MCN.13 Other monoclonal FLCmediated pathologies can co-exist with proximal
tubule fibrosis and MCN, including light-chain
amyloidosis, monoclonal immunoglobulin deposition disease, acquired Fanconi syndrome, and
acute tubular necrosis.3,4 Additional factors that
contribute to RI include dehydration, hypercalcemia, and the use of nephrotoxic drugs (e.g. nonsteroidal anti-inflammatory drugs, contrast media,
particular antibiotics, and certain anticancer treatments).4,14 The median age at diagnosis of MM is
approximately 70 years;15 as such, normal agerelated decline in renal function and the presence
of comorbidities that often increase with age (e.g.
Type II diabetes, heart failure, and atherosclerotic
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Figure 1. Pathology of monoclonal free light chain-mediated proximal tubule damage and cast nephropathy.
Proximal tubule cell injury occurs as a result of excessive endocytosis of the free light chains via the cubilin–
megalin complex, terribly activating apoptosis and inflammation. In the distal tubules, free light chains bind to
the complementarity determining region 3 domain on Tamm-Horsfall proteins and coprecipitate to form casts.
Cast formation and nephronal occlusion leads to progressive interstitial inflammation and fibrosis.6
CDR3, complementarity determining region 3; FLC, free light chain; THP, Tamm-Horsfall protein.

vascular disease) could exacerbate RI among
patients with MM.
Early advances in the treatment of patients
with MM and RI
In the era of conventional chemotherapy for MM,
RI was present in roughly twice as many earlydeath patients compared with those who survived
longer than 60 days.16 A single-institution study17
of 423 patients with MM treated with conventional chemotherapy showed that baseline RI was
associated with a significantly lower response to
chemotherapy. Both response to chemotherapy
and severity of RI were independent factors associated with survival.
Major improvements in survival of patients with
MM and RI resulted from the introduction of
novel agents such as early immunomodulatory
drugs (thalidomide, lenalidomide), the first PI
(bortezomib), and monoclonal antibodies (e.g.

journals.sagepub.com/home/tah

isatuximab, daratumumab).18–20 A retrospective
analysis18 of over 1700 patients with symptoma
tic MM (roughly 50% of which had an
eGFR < 60 mL/min/1.73 m2) treated between
1990 and 2011 found that upfront use of novel
agents (mostly thalidomide and bortezomib) was
independently associated with a reduced risk
of early death (hazard ratio (HR) 0.446; 95%
confidence interval (CI): 0.24–0.83; p = 0.009).
Another retrospective analysis19 of 1538 patients
with MM treated between 2000 and 2011, including 680 with RI at diagnosis, found that the use of
novel agents (i.e. thalidomide, lenalidomide, and
bortezomib) as first-line therapy significantly
improved median OS compared with conventional chemotherapy (60 versus 21 months,
respectively; log-rank p < 0.001).
Novel RRMM treatments for patients with RI
Although the aforementioned investigations were
conducted in the setting of front-line therapy for
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NDMM, the profound impact of novel agents on
patients with RI extends to the RRMM setting.
Adjunctive treatment with high cut-off hemodialysis (HCO-HD), which utilizes membranes with
larger pore size than conventional HD membranes
and facilitates the removal of monoclonal FLCs,21
has been suggested as a means to induce renal
recovery and independence from dialysis in
patients with RI and MM.13 Independent phase
II22 and phase III23 randomized controlled trials
confirmed greater reduction of monoclonal FLCs
with HCO-HD compared with standard high-flux
HD, though neither showed a significant difference in the primary outcome of HD independence
at 90 days. A recent meta-analysis, which included
data from these two randomized trials as well as
from three observational studies, noted heterogeneity between study populations but found no difference in survival or renal benefits with HCO-HD
versus conventional HD, though a trend toward
higher dialysis independence was seen in the
HCO-HD group.24 Hemodiafiltration with ultrafiltrate regeneration offers an alternative approach
to removing monoclonal FLCs and has been associated with less albumin loss than HCO-HD.25 A
small observational study26 suggested that hemodiafiltration with ultrafiltrate regeneration may
result in sustained FLC reduction with potential
for renal recovery in patients with RI and MM.
Large-scale, randomized studies will be needed to
better characterize the adjunctive impact of
HCO-HD and hemodiafiltration with ultrafiltrate
regeneration on clinical outcomes in patients with
RI and MM.
The remainder of this section will review existing
and emerging evidence for the efficacy and safety
of novel systemic agents in patients with RRMM
and RI, with a focus on subgroup analyses from
pivotal phase III randomized clinical trials (Table
2). Renal response data, particularly those in conformance with IMWG criteria1 for renal response,
are summarized in Table 3. Real-world experience in patients with RRMM and RI will be discussed throughout.
Immunomodulatory drug-based regimens
Thalidomide and later-generation immunomodulatory drugs (i.e. lenalidomide and pomalidomide)
have anti-angiogenic, immunomodulatory, and
direct cytotoxic effects on myeloma cells.27
Lenalidomide is largely excreted unchanged in the
urine and requires dose adjustment for different
4

levels of renal function.28,29 The approval of lenalidomide + dexamethasone (Rd) for patients with
RRMM was based on two pivotal phase III trials,
MM-00930 and MM-010.31 A retrospective analysis32 of the 353 patients randomized to Rd during
these two trials was conducted to investigate the
efficacy and safety of the combination in patients
with RRMM and various degrees of RI. Of the
353 patients, 82 (24%) had moderate RI
(CrCl ⩾ 30 to < 60 mL/min) and 16 (5%) had
severe RI (CrCl < 30 mL/min). After a median
follow-up of 31.3 months, OS for patients with
moderate or severe RI was significantly shorter
than for patients with mild or no RI (29.0 and
18.4 months, respectively, compared with
38.9 months; p = 0.006 for both comparisons).
The majority (72%) of patients with moderate-tosevere RI experienced at least one level of improvement in CrCl (i.e. from severe to moderate or
from moderate to mild or no RI). Higher levels of
RI were associated with greater risk of grade 3 or
4 adverse events (AEs) including thrombocytopenia, neutropenia, anemia, and pneumonia.
Phase II trials33,34 and several small real-world
studies35–37 of patients with RRMM and RI have
reported similar efficacy and safety data for Rd.
One real-world study36 examined the efficacy of
Rd in patients with RI and its impact on RI reversal (according to IMWG criteria,1 Table 1).
Twelve of 50 patients studied had RI (defined as
CrCl < 50 mL/min). Partial response (PR) or better was documented in 58% of patients with RI
(similar to the 60% ⩾ PR rate in patients without
RI); median progression-free survival (PFS) and
median OS were also similar between patients
with and without RI (9 versus 8 months and 14
versus 16 months, respectively). Five of the 12
patients (42%) with RI achieved a renal response
to Rd (three achieved a complete renal response
(CRR) and two achieved a minor renal response).
Unlike lenalidomide, pomalidomide is extensively
metabolized by the liver, with limited renal clearance of active drug.38 Pomalidomide + low-dose
dexamethasone (Pd) was approved for RRMM
based on results from the pivotal, phase III
MM-003 trial,39 which compared the combination
to high-dose dexamethasone alone. A post hoc
analysis40 of 447 patients from MM-003 examined
the impact of baseline renal function (CrCl ⩾ 30
to < 60 mL/min versus CrCl ⩾ 60 mL/min) on
efficacy and safety. Median PFS was similar
between study arms regardless of baseline renal
journals.sagepub.com/home/tah
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Kd (n = 18)

Isa-Kd (n = 43)

Pd (n = 49)

Isa-Pd (n = 55)

Kd (n = 27)

Dara-Kd (n = 38)

Vd (n = 70)

Dara-Vd (n = 57)

Pd (n = 47)

Dara-Pd (n = 40)

Rd (n = 65)

Dara-Rd (n = 80)

Vd (n = 99)

Kd (n = 85)

Rd (n = 82)

KRd (n = 79)

Vd (n = 28)

eGFR ⩾ 15 to < 60 mL/min/1.73 m2

eGFR ⩾ 30 to < 60 mL/min/1.73 m2

CrCl ⩾ 15 to < 50 mL/min

CrCl ⩾ 20 to ⩽ 60 mL/min

CrCl ⩾ 30 to ⩽ 60 mL/min

CrCl ⩾ 30 to < 60 mL/min

CrCl ⩾ 15 to
< 50 mL/min

CrCl ⩾ 30 to < 60 mL/min

CrCl ⩾ 30 to < 60 mL/min

CrCl ⩾ 30 to < 60 mL/min

Cut-off for RI

NR
13.4

2 (1–4)

3.7

3 (2–10)
2 (1–4)

9.5

NA

2 (1–2)
3 (2–11)

NA

2 (1–2)

6.5

6.1

2 (1–5)

2 (1–10)

12.1

2 (1–5)

NR

11.3b

1 (1–8)

2 (1–9)

33.6b

1 (1–11)

6.5

14.9

17.6

2 (1–3)
(1–3)

26.3

9.5

2 (1–2)
2 (1–3)

15.1

1.9

5 (2–17)
2 (1–2)

4.0

0.27
(0.11; 0.66)

0.50
(0.30; 0.85)

0.44
(0.19; 1.00)

0.55
(0.30; 1.02)

0.59
(0.35; 0.99)

0.41
(0.26; 0.65) b

0.49
(0.32; 0.76)

0.69
(0.57; 0.83)

0.67
(0.34; 1.34)

0.48
(0.33; 0.70)

NA

NA

11.6

NR

NE

NE

NA

NA

NA

NA

NR

NR

23.7

42.1

NA

NA

NA

NA

4.9

10.4

NA

0.53
(0.30; 0.96)

0.75
(0.49; 1.13)

NA

NA

–

0.66
(0.44; 0.99)

0.72
(0.51; 1.02)

NA

0.65
(0.44; 0.96)

HR
(95% CI)

Months

Months

HR
(95% CI)

Median OS

Median PFS

5 (2–12)

Median
(range)
prior lines

61.1

93.1

24.5

56.4

75

84

63.2

82.9

46

69

68

91

49.5

74.1

66.7

87.1

53.6

91.4

11

28

ORR, %

11.1

30.2

0

5.5

3

14

NA

NA

2

9

5.3

30.4

NA

NA

NA

NA

NA

NA

NA

NA

MRD– rate
(10‒5
sensitivity), %

18

43

47

54

153

308

237

243

150

149

281

283

97

85

389

392

270

278

150

300

n

Safety

77.8

79.1

79

91

74

82

62

76

NA

NA

80.8

90.1

79

87

80.7

83.7

NA

NA

NA

NA

Grade ⩾ 3
AEs, %

77.8

62.8

60

78

46

56

NA

NA

39

50

NA

NA

NA

NA

53.7

59.7

42

57

53

61

Serious
AEs, %

aMM-003

AE, adverse event; CI, confidence interval; CrCl, creatinine clearance; d, dexamethasone; Dara, daratumumab; HR, hazard ratio; Isa, isatuximab; K, carfilzomib; MRD–, minimal residual disease-negative; NA,
not available; NE, not estimable; NR, not reached; ORR, overall response rate; OS, overall survival; P, pomalidomide; PFS, progression-free survival; R, lenalidomide; RI, renal impairment.
compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone monotherapy.
bData from extended follow-up analysis of POLLUX;46 similar to data from the first interim analysis48 (median PFS NR versus 11.4 months; HR 0.36; 95% CI: 0.22–0.60).

IKEMA53

ICARIA-MM52

CANDOR51

CASTOR50

APOLLO49

POLLUXb46,47,48

ENDEAVOR45

ASPIRE43,44

PVd (n = 35)

da (n = 56)

Pda (n = 93)

MM-00339,40

OPTIMISMM41,42

Treatment (number
of patients in RI
subgroup)

Trial

Table 2. Subgroup analyses of patients with RRMM and RI from select pivotal phase III trials (darker shading: data for subgroup analysis; no shading: data for the
overall population).
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Table 3. Renal response data from subgroup analyses of patients with RI in pivotal phase III clinical trials.
Trial

Definition of RI

na

Normal
renal
function

RI

Treatment
arms
experimental
vs comparator

Complete
renal
response
(%; reversal
of renal
impairment)b

Median time to
complete renal
response (weeks)
Normal
renal
function

RI

MM-00340

CrCl < 60 mL/min (RI)
vs CrCl ⩾ 60 mL/min
(normal renal function)

298

149

Pd vs dc

32 vs 43

NA

NA

OPTIMISMM42

CrCl < 60 mL/min (RI)
vs CrCl ⩾ 60 mL/min
(normal renal function)

163

63

PVd vs Vd

NA

1.1 vs 4.9d

3.1 vs 3.6d

ENDEAVOR45

CrCl < 50 mL/mine

NAe

184e

Kd vs Vd

15.3 vs 14.1

–

8.1 vs 6.4

ICARIA-MM52

eGFR < 60 mL/min/1.73
m² (RI) vs eGFR ⩾ 60mL/
min/1.73m² (normal renal
function)

183

104

Isa-Pd vs Pd

71.9 vs 38.1

–

3.4 vs 7.3

IKEMA53

eGFR < 60mL/min/1.73m²
(RI)
vs eGFR ⩾ 60mL/
min/1.73m²
(normal renal function)

215

61

Isa-Kd vs Kd

52.0 vs 30.8

–

7.8 vs NC

CrCl, creatinine clearance; d, dexamethasone; eGFR, estimated glomerular filtration rate; IMWG, International Myeloma Working Group;
Isa, isatuximab; K, carfilzomib; NA, not available; NC, not calculable; P, pomalidomide; RI, renal impairment; V, bortezomib.
aNumber of patients with known CrCl levels.
bComplete renal response defined as improvement in eGFR from < 50 mL/min/1.73 m² at baseline to ⩾ 60 mL/min/1.73 m² (no renal impairment)
in at least one post-baseline assessment, per IMWG recommendations.
cMM-003 compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone monotherapy.
dTime to first improvement in renal function.
ePatients were divided into renal subgroups by CrCl ⩾ 15 to < 50, ⩾ 50 to < 80, and ⩾ 80 mL/min, but a formal definition of RI was not made;
184 patients had CrCl ⩾ 15 to < 50 mL/min.

function, and OS benefit versus high-dose dexamethasone was sustained in patients with baseline
CrCl ⩾ 30 to < 60 mL/min (Table 2). Renal
response, based on IMWG criteria, was similar
between groups (Table 3). Rates of grade 3/4 AEs
were similar across renal function subgroups.
Similar results were seen in a pooled analysis54
of patients with RRMM and moderate RI
(CrCl ⩾ 30 mL/min to < 60 mL/min) from
MM-003 and two other trials of Pd (MM-002
(phase I/II) and MM-010 (phase III)). In this analysis, median OS was shorter for patients with moderate RI versus those without RI (10.5 versus
14.0 months; p = 0.004). Though not designed to be
comparative in nature, the phase II MM-013 trial55

6

is unique in that it prospectively investigated Pd in
81 patients with RRMM and moderate RI
(eGFR ⩾ 30 to < 45 mL/min/1.73 m2), severe RI
(eGFR < 30 mL/min/1.73 m2), or severe RI requiring hemodialysis. Median OS was 16.4 months,
11.8 months, and 5.2 months in the three groups,
respectively, and renal response (as defined by
IMWG)1 was achieved by 18.2%, 35.3%, and 7.1%
of patients. A small real-world study56 examined
efficacy and safety of Pd in 70 patients, of which 12
(17.1%) had an eGFR < 45 mL/min/1.73 m2.
Median PFS and OS for the eGFR < 45 versus ⩾ 45 mL/min/1.73 m2 groups were 3.7 versus
5.2 months and 7.4 versus 14.1 months, respectively;
neither difference reached statistical significance
and AE rates were similar between the groups.
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In total, available data show that patients with RI
and RRMM achieve survival benefit from the
addition of lenalidomide or pomalidomide to
dexamethasone, though generally to a lesser
extent than patients without RI.32,54 Prospective,
late-phase renal response data for the immunomodulatory drugs are limited, but retrospective and real-world data for Rd32,36 and phase II
data for Pd55 show that improvement in renal
function is possible when these agents are added
to dexamethasone.
Proteasome inhibitor-based regimens
Proteasome inhibitors (i.e. bortezomib, carfilzomib, and ixazomib) exert their effects on myeloma cells through a variety of mechanisms
including activation of apoptotic pathways, inhibition of angiogenesis, and alteration of cell adhesion.57 Regimens containing bortezomib, the
first-in-class proteasome inhibitor, have long been
considered the standard of care for patients with
MM and RI, owing largely to its nonrenal metabolism and the breadth of evidence supporting its
efficacy in this patient population.1,14 Following
its initial FDA approval for MM in 2003, multiple studies have demonstrated the ability of bortezomib-based regimens to induce rapid and
significant response, with potential RI reversal, in
patients with RRMM.58–64
The utility of adding pomalidomide to the combination of bortezomib + dexamethasone (PVd)
was demonstrated in the phase III OPTIMISMM
trial.41 A post hoc analysis42 of the 226 patients
who had received one line of prior therapy compared the efficacy and safety of PVd versus bortezomib + dexamethasone (Vd) by renal status
(CrCl < 60 versus ⩾ 60 mL/min; dialysis patients
excluded). Treatment with PVd numerically
improved median PFS in the CrCl < 60 mL/min
group, whereas the overall response rate (ORR)
was improved in both renal groups (Table 2). No
new safety signals emerged for the PVd combination in patients with RI. The median time to first
improvement in renal function was numerically
shorter with PVd in both the RI (Table 3) and
non-RI groups.
The phase III ASPIRE trial43,44 led to the approval
of carfilzomib (with lenalidomide + dexamethasone; KRd) in patients with RRMM. At a median
follow-up of 67.1 months, the final analysis of
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ASPIRE reported OS for the prespecified subgroups of patients with CrCl ⩾ 30 to < 60 mL/min
(n = 161) and ⩾ 60 mL/min (n = 624). OS HRs
favored KRd for both subgroups and were similar to
results for the overall study population (Table 2).43
A prespecified subgroup analysis65 of the phase III
A.R.R.O.W. study (once- versus twice-weekly carfilzomib in RRMM; patients with CrCl ⩾ 30 mL/min
enrolled) reported consistent PFS and ORR
improvement with once-weekly dosing across all
renal function subgroups (CrCl < 50 mL/min (n =
85), CrCl ⩾ 50 to < 80 mL/min (n = 202), and
CrCl ⩾ 80 mL/min (n = 190)).
The randomized phase III ENDEAVOR trial66
compared carfilzomib + dexamethasone (Kd)
with bortezomib + dexamethasone (Vd) for
patients with RRMM, revealing improvement in
the primary outcome of PFS with Kd. A post hoc
exploratory subgroup analysis45 evaluated the efficacy and safety of both treatment regimens in
patients with various degrees of RI at baseline
(grouped by CrCl ⩾ 15 to < 50 (n = 184),
CrCl ⩾ 50 to < 80 (n = 363), and CrCl > 80 mL/
min (n = 382)). Improvements in PFS, OS, and
ORR were observed in the Kd arm across renal
subgroups; results for patients with CrCl < 50 mL/
min are highlighted in Table 2. In patients with
CrCl ⩾ 15 to < 50 mL/min, roughly 15%
achieved CRR and time to complete renal response
was similar across treatment arms (Table 3).
A large real-world study67 utilized electronic medical record data from US oncology clinics to compare renal response rates (as defined by IMWG;1
Table 1) among patients with RRMM and RI
(defined as baseline eGFR < 50 mL/min/1.73 m2)
who were treated with Kd (n = 543) or Vd (n = 1005)
in the second through fourth line of treatment. For
patients receiving second-line treatment, those who
received Kd versus Vd demonstrated significantly
better renal overall response rates (51.4% versus
39.6%; log-rank p < 0.0001) and renal complete
response rates (26.6% versus 22.2%; log-rank
p = 0.0229). Consistent results were observed
among patients in the third- and fourth-line settings and among patients in the second-line setting
with eGFR < 15 mL/min/1.73 m2. A combined
analysis of patients from both treatment groups
(and across second through fourth lines of treatment) found that patients who achieved renal
response had longer OS and time to next treatment
(TTNT) than renal nonresponders.67
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Ixazomib, an oral proteasome inhibitor approved
for use in RRMM, was approved in combination
with Rd based on results of the phase III
TOURMALINE-MM1 trial.68 Patients with
mild-to-moderate RI (CrCl ⩾ 30 to 60 mL/min)
comprised 25% of the 722 patients in the trial.
Though no prespecified or post hoc subgroup
analyses have been performed for patients with
RI, the relatively large contribution of these
patients to overall trial results suggests that ixazomib benefits can be safely extended to patients
with CrCl ⩾ 30 mL/min.
Overall, substantial evidence for the benefit of
bortezomib and carfilzomib exists for patients
with RI and RRMM, though analyses of renal
subgroups within phase III trials were largely post
hoc in nature. The phase III ENDEAVOR trial45
revealed superior efficacy with Kd versus Vd in
patients with RI and RRMM, with similar renal
response rates and time to renal response between
arms. A large real-world study67 showed improved
overall and complete renal response rates with Kd
versus Vd, and renal response was associated with
improved OS. Phase III data specific to patients
with RI has not been reported for ixazomib.
Real-world benefit of combining immunomodulatory drugs and proteasome inhibitors. Building on
experiences from the OPTIMISMM trial,
researchers utilized the Flatiron Health database
to assess outcomes and renal response by firstand second-line drug class (i.e. PIs, immunomodulatory drugs, and monoclonal antibodies)
among patients with MM and RI (defined as
eGFR < 50 mL/min/1.73 m2).69 Though patients
who received monoclonal antibodies were
included in the analysis, low treatment rates with
these therapeutics during the study period (2011–
2019) precluded robust analyses of outcomes
with this drug class. After adjustment for multiple
factors, patients with RI at the start of second-line
treatment had worse OS compared with non-RI
patients (median 2.67 versus 4.44 years, respectively; adjusted HR 1.49; 95% CI: 1.33–1.68).
Among 920 patients with RI at the start of second-line therapy who received at least one eGFR
measurement during treatment, 19% achieved a
CRR. Patients who received a PI + immunomodulatory drug combination were significantly
more likely to have a CRR than those without use
of either treatment class (adjusted OR: 3.89; 95%
CI: 1.71–8.86), and those who achieved a CRR
with the combination had significantly improved
8

OS compared to those not receiving either treatment who did not achieve CRR (adjusted HR:
0.53; 95% CI: 0.32–0.88). Results from this study
confirmed the association of RI with inferior OS
in patients with RRMM and highlighted both the
benefit of combining PIs with immunomodulatory drugs in early lines of therapy and the significance of achieving CRR.
Monoclonal antibody-based regimens
Monoclonal antibodies (i.e. daratumumab,
isatuximab, and elotuzumab) exert their antitumor activity via immune-mediated mechanisms
that selectively target myeloma cells with minimal
impact on normal tissue.20,70 Daratumumab is a
CD38 monoclonal antibody approved as monotherapy and in multiple combinations for the
treatment of patients with relapsed/refractory disease. A pooled analysis71 of the two noncomparative studies (phase I/II GEN501 and phase II
SIRIUS) that led to the approval of daratumumab
monotherapy in patients with RRMM revealed
that 37% of patients had a baseline CrCl of ⩾ 30
to < 60 mL/min. The ORR (27.8%) in that subgroup was consistent with that observed in the
overall combined population (31.1%).
In the pivotal phase III POLLUX trial,47 which
compared daratumumab + lenalidomide + dexamethasone (Dara-Rd) to Rd in patients with
RRMM, the primary end point of PFS was significantly lengthened with the addition of daratumumab.46,47 Patients with CrCl ⩾ 30 mL/min
were allowed to enroll in POLLUX, and a post
hoc subgroup analysis48 at the time of the first
interim analysis found that the PFS benefit seen
in the overall study population was maintained in
patients with moderately impaired renal function
(defined as CrCl ⩾ 30 to < 60 mL/min). The
PFS benefit was maintained after an extended
follow-up period and the ORR was also higher in
patients with RI who received daratumumab
(Table 2). The phase Ib trial72 of daratumumab + pomalidomide + dexamethasone
(Dara-Pd) versus Pd (EQUULEUS, n = 103)
included 31 patients with a baseline CrCl
of < 60 mL/min (those with CrCl of ⩾ 45 mL/
min were eligible for enrollment). The ORR in
this prespecified subgroup of patients was 58.1%,
similar to that for the overall study population
(60.2%). The phase III trial49 of Dara-Pd versus
Pd (APOLLO, N = 304) allowed patients with
CrCl ⩾ 30 mL/min to enroll. Patients in the
journals.sagepub.com/home/tah
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Real-world experience of daratumumab in
patients with RI is also available. Case reports74–77
and a small case series78 of dialysis-dependent
patients with RRMM who received daratumumab-based therapy have consistently reported
benefit, in some instances with reduction of dialysis frequency75,76 or full dialysis independence.74,77

Table 4. Phase II studies in patients with RRMM and RI.

The phase II DARE study73 of daratumumab +
dexamethasone enrolled 38 patients with RRMM
and severe RI (defined as either eGFR < 30 mL/
min/1.73 m2 or requiring hemodialysis). At study
initiation, 17 patients (48.6%) were on dialysis. A
preliminary analysis of efficacy and safety was
conducted for 35 patients who were at least
5 months into treatment. The 6-month PFS rate
for the overall population was 50%, with an ORR
of 45.7%. In patients requiring dialysis, the ORR
was 35.3%. The renal response rate (as defined
by IMWG;1 Table 1) was 17.1% (Table 4).

Safety

The pivotal phase III CASTOR trial50 provided
the basis for the approval of daratumumab + bortezomib + dexamethasone (Dara-Vd) for the
treatment of RRMM. CASTOR, which compared Dara-Vd to Vd alone, allowed patients with
CrCl > 20 mL/min at screening to enroll. Patients
in the prespecified subgroup of CrCl ⩽ 60 mL/
min comprised 23% (57 of 243) and 30% (70 of
233) of patients with evaluable CrCl at baseline in
the Dara-Vd and Vd groups, respectively. Median
PFS benefit in these patients (Table 2) was similar to that for the overall study population.
CANDOR,51 the phase III trial of daratumumab + carfilzomib + dexamethasone
(Dara-Kd) versus Kd, allowed enrollment of
patients with CrCl ⩾ 20 mL/min at screening. A
prespecified subgroup analysis of PFS by level of
baseline renal function (⩾15 to 50, ⩾ 50 to < 80,
and ⩾ 80 mL/min) was performed. Patients with
CrCl ⩾ 15 to < 50 mL/min comprised 12% of
patients (38 of 311) in the Dara-Kd group and
18% of patients (27 of 154) in the Kd group with
evaluable CrCl at baseline. The PFS benefit seen
with Dara-Kd in the overall population was
extended to patients with CrCl ⩾ 15 to < 50 mL/
min (Table 2).

N/n

Grade ⩾ 3
AEs, %

Serious
AEs, %

prespecified subgroup of CrCl ⩽ 60 mL/min
comprised 26% (40 of 151) and 31% (47 of 153)
of patients in the Dara-Pd and Pd groups, respectively. Median PFS benefit in these patients
(Table 2) was similar to that for the overall study
population.

61.8
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A retrospective, single-center study80 analyzed 91
patients with RRMM who received daratumumab
as monotherapy or in combination with novel
agents. Patients were grouped by renal function
(eGFR < 30 (n = 11), ⩾ 30 to 60 (n = 27),
and ⩾ 60 mL/min/1.73 m2 (n = 53)). Median
PFS was similar across groups (17.5, 22.4, and
17.3 months, respectively), and 11 patients in the
eGFR ⩾ 30 to < 60 mL/min/1.73 m2 group
achieved a renal response (defined as eGFR >
60 mL/min/1.73 m2 in two consecutive visits for
patients with baseline RI).
Isatuximab is a monoclonal antibody that binds
to a specific epitope of the CD38 receptor and
possesses the unique ability to induce direct apoptosis of myeloma cells.81 The first approval of
isatuximab resulted from the pivotal phase III
ICARIA-MM trial,82 which compared isatuximab + pomalidomide + dexamethasone
(Isa-Pd) to Pd in patients (N = 307) with RRMM.
ICARIA-MM enrolled patients with eGFR ⩾
30 mL/min/1.73 m2,82 and efficacy and safety outcomes were examined in a prespecified subgroup
analysis52 of patients with RI (defined as
eGFR < 60 mL/min/1.73 m2). Of 287 patients
with evaluable eGFR at start of therapy, 55
(38.7%) in the Isa-Pd group and 49 (33.8%) in
the Pd group had RI; each arm included one
patient with eGFR < 30 mL/min/1.73 m2. The
PFS benefit of Isa-Pd versus Pd was consistent
with that seen for the full study population, and
ORR and minimal residual disease (MRD) negativity rates were higher with the addition of isatuximab in patients with RI (Table 2). Unique
among phase III trials of anti-CD38 monoclonal
antibodies, the ICARIA-MM RI subgroup analysis also evaluated renal response rates and AE
rates to therapy among patients with RI at baseline. Complete renal response rates were 71.9%
with Isa-Pd and 38.1% with Pd, respectively.
Median time to renal response also improved in
the Isa-Pd arm (Table 3). Among patients with
RI, grade ⩾ 3 and treatment-emergent adverse
events (TEAEs) were more common in the Isa-Pd
group. However, when adjusted for increased
treatment exposure in the Isa-Pd arm, the event
rate of serious TEAEs per patient year for patients
with RI was similar across groups.52
Isatuximab is also approved in combination with
carfilzomib + dexamethasone for the treatment
of patients with RRMM, based on results from
the pivotal phase III IKEMA trial (N = 302).83
10

IKEMA allowed enrollment of patients with
eGFR as low as 15 mL/min/1.73 m2,83 and a prespecified subgroup analysis53 examined efficacy,
renal response, and safety in patients with RI
(defined as eGFR < 60 mL/min/1.73 m2) at the
time of the interim analysis. Patients with RI
(n = 43 in the isatuximab + carfilzomib + dexamethasone (Isa-Kd) group and n = 18 in the Kd
group) comprised 26.1% and 16.2% of patients
in their respective study arms with evaluable
eGFR at baseline. Roughly 2.5% of patients in
each study arm had an eGFR of ⩾ 15 to < 30 mL/
min/1.73 m2. For patients with RI, PFS benefit
with the addition of isatuximab was consistent
with that seen for the overall study population;
overall response and MRD negativity rates among
patients with RI were higher in the Isa-Kd
arm (Table 2). Complete renal response rates
improved with Isa-Kd (52.0%) versus Kd
(30.8%), as did time to first renal response (Table
3). Patients with eGFR < 30 mL/min/1.73 m2 at
baseline were more likely to achieve minor renal
response with the addition of isatuximab. Isa-Kd
was associated with a manageable safety profile in
patients with and without RI. Notably, the presence of RI was not associated with higher rates of
grade 3 or higher cardiac failure, which is a known
toxicity of carfilzomib.53
Real-world experience of isatuximab in patients
with RI is also available. A case report84 of a dialysis-dependent patient with RRMM who received
therapy with Isa-Pd was recently published.
Following seven prior lines of therapy, the
patient’s free light chain λ level dropped from
2,070 mg/L to 412 mg/L 12 days after starting
Isa-Pd. The patient experienced no infusion reactions or clinically meaningful drops in white blood
cell count during treatment with Isa-Pd, and his
disease remained well controlled after seven
cycles of treatment.
Elotuzumab is a humanized monoclonal antibody
targeted against signaling lymphocyte activation
molecule-7 (SLAMF7). Two phase III randomized
trials, ELOQUENT-285 and ELOQUENT-3,86 led
to the approval of elotuzumab with Rd and Pd,
respectively. Enrollment was allowed for patients
with CrCl ⩾ 30 mL/min (ELOQUENT-2) and ⩾
45 mL/min (ELOQUENT-3), but neither trial
reported on safety or efficacy outcomes stratified
by renal function. A small phase Ib study70 found
elotuzumab to be both tolerable and effective for
treatment of patients with MM and RI, including
journals.sagepub.com/home/tah
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those with end-stage renal disease. Enrollment was
allowed for patients with three levels of renal function: normal (CrCl ⩾ 90 mL/min (n = 8)), severely
impaired (CrCl < 30 mL/min, not requiring dialysis (n = 9)), and end-stage (requiring dialysis (n =
9)). Overall responses occurred in 75%, 67%, and
56% of patients in the three renal function groups,
respectively, and two patients in the severe RI
group (including one with RRMM) achieved a
minor renal response (as defined by the IMWG;1
Table 1). No difference in grade 3/4 AEs was
observed between renal function groups. The efficacy and safety observed in patients with RI during
this small phase Ib trial has not been confirmed in
late-phase clinical trials.
In total, the dramatic efficacy benefits seen in
phase III trials of daratumumab and isatuximab
in RRMM extend to subgroups of patients with
RI. Phase II data73 and numerous real-world
experiences have indicated that improvement of
renal function is possible with daratumumab;
however, phase III trials of daratumumab-based
regimens have not reported on renal response
rates. Phase III trials52,53 of isatuximab-based regimens have provided robust analyses of efficacy,
safety, and renal response data for patients with
RI. Late-phase data for elotuzumab have not
been reported separately for the population of
patients with RI.
Antibody-drug conjugates
Belantamab mafodotin is a first-in-class ADC that
delivers a microtubule-disrupting agent, monomethyl auristatin F, to B-cell maturation antigen
(BCMA)-expressing myeloma cells.87 Belantamab
mafodotin received FDA approval in patients with
RRMM based on the phase II DREAMM-2
study.88 Patients with eGFR ⩾ 30 mL/min/1.73
m2 at screening were allowed to enroll in
DREAMM-2. A post hoc analysis79 was conducted
to explore efficacy and outcomes across patients
with varying levels of renal function at enrollment:
normal (eGFR ⩾ 90 mL/min/1.73 m2), mildly
impaired (⩾60 to < 90 mL/min/1.73 m2), and
moderately impaired (⩾30 to < 60 mL/min/1.73
m2)). Patients with moderate RI comprised roughly
25% of patients in each dosing cohort. Overall
response rates were similar across renal function
groups and consistent with results for the overall
DREAMM-2 study population. Median PFS was
similar among patients with and without any
degree of RI, as were rates of keratopathy and
journals.sagepub.com/home/tah

grade 3/4 AEs. Results for the moderate RI group
are detailed in Table 4.
CAR T-cell therapies
Based on results from the phase II KarMMA
trial,89 idecabtagene vicleucel became the first
FDA-approved, BCMA-directed chimeric antigen receptor (CAR) T-cell therapy. Though
patients with inadequate renal function (defined
as CrCl ⩽ 45 mL/min) were excluded from the
KarMMa trial,89 two small studies offer some
insight into outcomes and safety of CAR T-cell
therapies among patients with RI. A post hoc
analysis90 of combined data from two phase I trials of different anti-BCMA CAR T-cell therapies
stratified patients (combined n = 59) according to
impaired renal function (IRF; defined as
eGFR < 90 mL/min/1.73 m2) and normal renal
function (NRF, eGFR ⩾ 90 mL/min/1.73 m2).
Patients with eGFR < 30 mL/min/1.73 m2 were
excluded from the analysis. Patients with IRF and
NRF had median PFS of 181 days versus 266 days
and median OS of 238 days versus 877 days (logrank p < 0.05 for each comparison), and eGFR
significantly improved in the IRF group over the
first 6 months of therapy. A small study91 of 7
patients with RRMM and RI (median stage 4
CKD92 (eGFR 15 to 29 mL/min/1.73 m2);
patients requiring dialysis excluded) explored
outcomes with CAR T-cell therapies directed at
either BCMA alone or the combination of BCMA
and CD19. All patients achieved response to
treatment, with 4 (57%) achieving stringent complete response. All patients also achieved renal
response, with 5 (71%) achieving renal complete
response. The median time to first renal response
was 9 days and median time to best renal response
was 32 days.
Selinexor
Selinexor is a first-in-class, oral selective inhibitor
of exportin-1 (XP01), a protein involved in the
exportation of tumor suppressor proteins from the
nucleus.93 Based on the phase IIb STORM trial,94
selinexor (in combination with low-dose dexamethasone) is FDA-approved for the treatment of
adult patients with RRMM who have received at
least four prior therapies (including PIs, immunomodulatory drugs, and an anti-CD38 monoclonal antibody). STORM enrolled 122 patients with
CrCl ⩾ 20 mL/min; CrCl was < 60 mL/min in 39
patients (32%) and < 40 mL/min in 14 patients
11
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(11%).94 A post hoc analysis95 of STORM compared outcomes among subgroups of patients with
varying renal function at baseline (CrCl < 40,
40–60, and > 60 mL/min). Across subgroups, the
ORR (35.7%, 16.0%, and 28.0%, respectively)
was similar to that of the overall study population
(26%), and 25%–67% of patients experienced an
increase in CrCl during treatment. The pivotal
phase 3 BOSTON trial96 provided the basis for
the approval of selinexor + bortezomib + dexamethasone for the treatment of adult patients with
MM who had received at least 1 prior therapy. Prespecified subgroup analyses of BOSTON,97 which
compared selinexor + bortezomib + dexamethasone to bortezomib + dexamethasone alone in 402
patients, examined outcomes by baseline renal
function (CrCl < 40 mL/min (n = 47), 40-60 mL/
min (n = 79), and > 60 mL/min (n = 276)). The
analyses confirmed clinical benefit from the addition of selinexor to bortezomib + dexamethasone
for patients with renal impairment.
Dose modifications for RI among novel agents
for the treatment of RRMM
Per the FDA’s 2020 Guidance Document,98 therapeutic proteins require a dedicated renal impairment study, with exception of proteins with a
molecular weight greater than 69 kDa. In the case
of treatments for RRMM, this exclusion applies to
monoclonal antibodies, ADCs, and CAR T-cell
therapies. Of the novel small molecules currently
used for the treatment of RRMM, ixazomib and
lenalidomide require dose adjustment for RI.
Though renal clearance of ixazomib is minimal,99 a
reduced starting dose (3 mg versus 4 mg) is recommended for patients with CrCl < 30 mL/min.100
Chen et al.28 reported that lenalidomide is predominantly excreted unchanged via the kidneys
and recommended dose adjustments based on
renal function. According to prescribing information29 for lenalidomide, on days 1–21 of 28-day
cycles, a daily dose of 25 mg is recommended
for patients with normal renal function (CrCl >
60 mL/min). In patients with IRF, 10 mg daily is
recommended for patients with CrCl ⩾ 30 to
< 60 mL/min, 15 mg every-other-day for patients
with CrCl < 30 mL/min not requiring dialysis,
and 5 mg daily for patients with CrCl < 30 mL/
min requiring dialysis (dose should be administered after dialysis). To better understand appropriate dosing of lenalidomide, and to prevent
under- or over-dosing among patients with RI,
12

the phase I/II PrECOG study101 analyzed the
maximum tolerated dose of lenalidomide in
patients with relapsed MM and RI, as well as the
efficacy and safety of lenalidomide + dexamethasone in these patients. Based on the absence of
dose-limiting toxicities during phase I, and on the
lack of difference in AEs and response rates
between daily and less frequent dosing in phase
II, the authors concluded that lenalidomide can
be given at full dose (25 mg daily) in patients with
a CrCl ⩾ 30 mL/min or at doses of at least 15 mg
daily to those with CrCl < 30 mL/min, even when
on dialysis, without the need to decrease the dose
frequency.
Conclusion
Renal impairment is a frequent complication of
MM that negatively impacts survival. Historically,
many trials have either excluded patients with RI
or failed to report outcomes in this important subset of patients. Phase III trials reporting efficacy
and safety data in patients with RRMM and RI
are summarized in Table 2. Though a key therapeutic goal in patients with MM and RI, improvement in renal function has not been uniformly
evaluated in late-phase clinical trials of novel therapies for RRMM (Table 3). Furthermore, the
majority of these studies are not powered to detect
differences between the treatment arms for
patients with RI. Real-world experiences supporting safety and efficacy, including renal response
and reversal of dialysis, have surfaced for various
novel RRMM regimens, adding to the evidence
base for selected treatments.
Treatment options for patients with RRMM are
rapidly expanding and improving outcomes, yet
the ideal treatment for patients with RI remains
unknown. Optimizing treatment of the underlying myeloma is critical in patients with RI, and
better MM therapies will be required to correct
the prognostic imbalance between patients with
RI and the general RRMM population. Despite
growing awareness of the negative impact of RI
on survival in patients with MM, the consistency
with which randomized controlled trials reported
enrollment criteria related to renal dysfunction,
prevalence of RI in enrolled patients, and outcomes among patients with RI did not significantly improve between 2005 and 2019.12
Available data for patients with RI and RRMM
stem largely from subgroup analyses of phase III
studies, comparisons among which are inherently
journals.sagepub.com/home/tah
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limited by differences in eligibility criteria between
trials (e.g. different CrCl cutoffs and exclusion of
patients with severe RI in some trials). These data
support the combination of monoclonal antibodies in combination with PIs or immunomodulatory drugs to be efficacious and safe in patients
with RI and RRMM. Reliable and consistent
reporting of efficacy and safety data for subgroups
of patients with RI, including data on renal
response and preferentially as part of prespecified
analyses, should be encouraged in future trials. In
addition, trials designed to prospectively evaluate
outcomes in large populations of patients with RI
(including those on dialysis) are essential to provide optimal myeloma therapy to this population.
Real-world data collected from robust databases
may supplement information provided from clinical trials and further support the translation of
study findings to real-world practice.102
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